Q Therapeutics, Inc., a developer of clinical-stage cell therapies for central nervous system (CNS) diseases, and REPROCELL Inc., Japan’s first induced pluripotent stem cell (iPSC) company, announced the formation of MAGiQ Therapeutics, Inc., a Japanese joint venture company. MAGiQ will develop iPSC-derived, glial-restricted progenitor cells (GRPs), in collaboration with Q Therapeutics and REPROCELL, to treat demyelinating and degenerative diseases of the CNS.
{iframe}https://globenewswire.com/news-release/2018/04/23/1485189/0/en/Q-Therapeutics-Announces-Joint-Venture-With-REPROCELL.html{/iframe}